Stephen Liu
MD
Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics
Georgetown Lombardi Comprehensive Cancer Center
Jun 24, 2025
Episode
295
Soundcloud
Share
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of taletrectinib, a next-generation ROS1 kinase inhibitor, for NSCLC with a ROS1 gene fusion. Dr. Enriqueta Felip and Dr. Jorge Nieva join the conversation to help review the data and offer to help place this new agent in the proper perspective.
Guest
Enriqueta Felip
MD, PhD
Director Thoracic Oncology Unit
Vall d’Hebron Institute of Oncology
Section in Chief, Medical Oncology Department, Vall d’Hebron University Hospital
Professor of Medicine, The University of Vic - Central University of Catalonia, Spain
Jorge Neiva
MD
Associate Professor of Clinical Medicine
University of Southern California/Norris Comprehensive Cancer Center
